Axios Biosciences


Overview

Axios Biosciences is a company revolutionizing oncology drug discovery by identifying drugs active in the tumor microenvironment, an important component of biology where tumors interact with non-malignant cells. These interactions can greatly affect the sensitivity of tumors to drugs. Our unique technology and approach, published in the journal Nature Medicine, allows us to identify novel drugs that traditional drug discovery approaches miss.

Management Team

Founder / President

Douglas McMillin

Doug is an entrepreneur with over 15 years experience in cancer and drug development research. He holds a PhD in Molecular & Systems Pharmacology from Emory University and completed a fellowship at the Dana-Farber Cancer Institute, Harvard Medical School. He has published >25 scientific papers, been a BioPharm America and Babson's BioIndustry Forum speaker and a sponsor for Harvard Business School's commercializing science and technology course.

Founder

Ashraf Haque

Ashraf has a degree in Economics & Math from Northwestern and MBA from Harvard Business School. He has spent time at Goldman Sachs, McKinsey & Company, ghSMART, an early stage consulting company, where he helped build the business into the leading management assessment firm serving private equity and venture capital clients.

CFO

Charlie Popkin

Charlie is a seasoned financial professional, with his a licensed CPA and MBA (Kellogg). His expertise includes executing business plans to profitability, capital fund raising, design and implementation of financial management systems, management reporting, budgets and forecasts. He's worked for Price Waterhouse, Deloitte & Touche, was the CFO of The Merallis Company founding management of PQC, Inc. and Medical Claims Management.

Consultant

Lee Piver

Lee is a successful business executive with >40 years experience in the pharmaceutical industry marketplace Lee has a degree in chemical engineering and an M.B.A. He has general manager and business development skills in the biotechnology, major pharmaceutical and chemical market sectors with Merck, Hoffmann LaRoche, Genzyme and Johnson Matthey. He worked at the Vice President level at Genzyme and Johnson Matthey in strategic management roles.

Douglas McMillin, PhD